Loading...

PE/Cyanine7 Streptavidin

Pricing & Availability
Regulatory Status
RUO
Other Names
SAv-PE/Cyanine7
Ave. Rating
Submit a Review
Product Citations
publications
PECyanine7_Streptavidin_Antibody_042123
Human peripheral blood lymphocytes were stained with PE/Cyanine7 streptavidin alone (open histogram) or Biotin anti-human CD3 (clone UCHT1) followed by (PE/Cyanine7) Streptavidin (filled histogram).
  • PECyanine7_Streptavidin_Antibody_042123
    Human peripheral blood lymphocytes were stained with PE/Cyanine7 streptavidin alone (open histogram) or Biotin anti-human CD3 (clone UCHT1) followed by (PE/Cyanine7) Streptavidin (filled histogram).
See PE/Cyanine7 spectral data
Cat # Size Price Quantity Check Availability Save
405206 100 µg 165€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Streptavidin binds to biotin with high affinity. Streptavidin - Phycoerythrin/Cyanine7 (PE/Cyanine7) is useful for detecting biotinylated antibodies. The excitation of PE/Cyanine7 by 488 nm laser light induces a light emission maximum of 775 nm.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human, Mouse, Rat, All Species
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
Streptavidin is conjugated with PE/Cyanine7 under optimal conditions.
Concentration
0.2 mg/ml (concentration relates to the Streptavidin only component of the conjugate)
Storage & Handling
The Streptavidin-PE/Cyanine7 solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

ICFC - Verified
Recommended Usage

Each lot of this Streptavidin-PE/Cyanine7 is quality control tested by immunofluorescent staining with flow cytometric analysis. The concentration provided is based upon molecular molar mass of streptavidin independent of any additional molecular mass that might be added by the PE/Cyanine7 conjugation.  For immunofluorescent staining, the recommended use of this reagent is =0.125 µg per 106 cells in 100 µl staining volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Streptavidin - Phycoerythrin/Cyanine7 (PE/Cyanine7) is useful as a second step reagent for indirect immunofluorescent staining, when used in conjunction with biotinylated primary antibodies. The average molecular weight of Streptavidin-PE/Cyanine7 is 360 kD and Streptavidin alone is 52 kD.

Application References
  1. Kamimura D, et al. 2006. J. Immunol. 177:306.
  2. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245.
  3. Anderson SM, et al. 2007. J. Exp. Med. doi:10.1084/jem.20062571. PubMed
  4. Rigolio R, et al. 2008. J Neuroimmunol. 199:67. PubMed
  5. Chappaz S, et al. 2010. J. Immunol. 184:3562. PubMed
  6. Weber SE, et al. 2011. J. Immunol. 186:432. PubMed
  7. Chamoto, K., et al. 2011. Am J Respir Cel Mol Biol. PubMed
  8. Ahuja, A., et al. 2011. J. Immunol. 187:3888. PubMed
  9. Chamoto K, et al. 2012. Am J Respir Cell Mol Biol. 46:283. PubMed
  10. Sugiura D, et al. 2012. PLoS One. 7:e44770. PubMed
  11. Nakamura M, et al. 2014. Mult Scler. PubMed
  12. Lyngaa R, et al. 2014. Clin Cancer Res. 20:1768. PubMed
  13. Shaw OM, et al. 2014. Rheumatology. PubMed
  14. Markey KA, et al. 2014. J Immunol. 192:5426. PubMed
  15. Yasunaga M, et al. 2014. Sci Rep. 4:4852. PubMed
  16. Nakamura M, et al. 2014. Mult Scler. 20:1371. PubMed
  17. Shaw OM, et al. 2014. Rheumatology. 53:1901. PubMed
  18. Tang AH, et al. 2014. EMBO J. 33:2782. PubMed
Product Citations
  1. Geng G, et al. 2021. Elife. 10: . PubMed
  2. Hu XX, et al. 2022. Acta Pharmacol Sin. 43:387. PubMed
  3. Goel RR, et al. 2022. Cell. 185:1875. PubMed
  4. Gargaro M, et al. 2022. Immunity. 55:1032. PubMed
  5. Hu Q, et al. 2022. Cell Rep. 40:111035. PubMed
  6. Weskamm LM, et al. 2022. Cell Rep Med. 3:100685. PubMed
  7. Pribluda A, et al. 2022. Elife. 11: . PubMed
  8. Weskamm LM, et al. 2022. STAR Protoc. 3:101902. PubMed
  9. Meyer S, et al. 2023. Cell Rep. 42:111995. PubMed
  10. Li Y, et al. 2020. Nat Commun. 2.350694444. PubMed
  11. Hu XF, et al. 2021. Theranostics. 3796:11. PubMed
  12. Tarazi S, et al. 2022. Cell. 185:3290. PubMed
  13. Takano T, et al. 2023. Nat Commun. 14:1451. PubMed
  14. Shao X, et al. 2023. Cell Discov. 9:44. PubMed
  15. Viborg N, et al. 2019. Oncoimmunology. 8:e1663107. PubMed
  16. Ahuja A, et al. 2011. J Immunol. 187:3888. PubMed
  17. Waide ML, et al. 2020. Cell Rep. 33:108503. PubMed
  18. Poon MML, et al. 2021. Sci Immunol. 6:eabl9105. PubMed
  19. Afroj T, et al. 2021. J Immunol. 206:1204. PubMed
  20. Zhou S, et al. 2020. Cell Res. 30:1063. PubMed
  21. Okuniewska M, et al. 2021. Cell Reports. 36(2):109368. PubMed
  22. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  23. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  24. Finke S 2010. J Immunol. 184:3562. PubMed
  25. Tang D, et al. 2020. Br J Haematol. 191:906. PubMed
  26. Khateb M, et al. 2022. Cell Rep. 40:111219. PubMed
  27. Han YH, et al. 2021. Science. 373:. PubMed
  28. Fachi JL, et al. 2020. J Exp Med. 217:00:00. PubMed
  29. Zheng H, et al. 2017. Sci Rep. 7:37. PubMed
  30. Kitano M, et al. 2016. Proc Natl Acad Sci U S A. 113: 1044 - 1049. PubMed
  31. Anderson S, et al. 2007. J Exp Med. 204:2103. PubMed
  32. Kunimoto H, et al. 2012. Sci Rep. 0.272916667. PubMed
  33. Terashima Y, et al. 2020. Nat Commun. 11:609. PubMed
  34. Zou T, et al. 2010. J Immunol. 185:2790. PubMed
  35. Gressler AE, et al. 2022. Front Immunol. 13:896255. PubMed
  36. Schenk R, et al. 2017. Cell Death Differ. 10.1038/cdd.2016.156. PubMed
  37. Chamoto K, et al. 2012. Am J Respir Cell Mol Biol. 46:283. PubMed
  38. Cheng HW, et al. 2019. Nat Commun. 10:1739. PubMed
  39. Friedman DJ, et al. 2021. Cancer Immunol Res. 9:952. PubMed
  40. Bahal R, et al. 2016. Nat Commun. 7:13304. PubMed
  41. Rowan A, et al. 2016. PLoS Pathog. 12:e1006030. PubMed
  42. Hansen UK, et al. 2020. Front Immunol. 11:373. PubMed
  43. Watson JK, et al. 2020. Sci Rep. 10:10490. PubMed
  44. Tarke A, et al. 2022. Cell. 185:847. PubMed
  45. Trinh T, et al. 2020. Leukemia. . PubMed
  46. Dawar S, et al. 2016. Cell Death Dis. 7:e2509. PubMed
  47. Schmid M, et al. 2016. PLoS One. 12: 1005676. PubMed
  48. Sebastian M, et al. 2016. J Immunol. 196: 144 - 155. PubMed
  49. Markey K, et al. 2014. J Immunol. 192:5426. PubMed
  50. Sugiura D, et al. 2012. PLoS One. 7:e44770. PubMed
  51. Matsumura M 2014. Sci Rep. 4:4852. PubMed
  52. Rando A 2014. EMBO J. 33:2782. PubMed
  53. Cassotta A, et al. 2020. J Exp Med. 217:00:00. PubMed
  54. Hermann BP, et al. 2018. Cell Rep. 25:1650. PubMed
  55. Delacher M, et al. 2020. Immunity. 52:295. PubMed
  56. Mueller A, et al. 2016. Nature. 540:276-279. PubMed
  57. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  58. Zhi Z, et al. 2021. Cell Death Differ. Online ahead of print.. PubMed
  59. Shaw O, et al. 2014. Rheumatology. 53:1901. PubMed
  60. Zeng W, et al. 2022. Nat Commun. 13:947. PubMed
  61. Dan JM, et al. 2021. Science. :371. PubMed
  62. Sebina I, et al. 2016. PLoS Pathog. 12:e1005999. PubMed
  63. Nakamura M, et al. 2014. Mult Scler. 20:1371. PubMed
  64. De Micheli AJ, et al. 2020. Cell Rep. 30:3583. PubMed
  65. Werner A, et al. 2021. iScience. 24:103076. PubMed
  66. Rigolio R, et al. 2008. J Neuroimmunol. 199:67. PubMed
  67. Kato Y, et al. 2015. J Immunol. 195: 1006-1014. PubMed
  68. Montes de Oca M, et al. 2016. PLoS Pathog. 12: 1005398. PubMed
  69. Ubags ND, et al. 2021. J Allergy Clin Immunol. 1049:147. PubMed
  70. Hidalgo San Jose L, et al. 2020. Cell Rep. 30:69. PubMed
  71. Halvarsson C, et al. 2019. Antioxid Redox Signal. 31:211. PubMed
  72. Tichy ED, et al. 2021. STAR Protoc. 2:100830. PubMed
  73. Tichy ED, et al. 2021. Cell Rep. 35:109098. PubMed
  74. Spath S, et al. 2022. iScience. 25:104998. PubMed
  75. Lyngaa R, et al. 2014. Clin Cancer Res. 20:1768. PubMed
  76. Getahun A, et al. 2016. J Exp Med. 213: 751 - 769. PubMed
  77. Pedersen NW, et al. 2019. Nat Commun. 10:837. PubMed
  78. Gozdecka M, et al. 2018. Nat Genet. 50:883. PubMed
  79. Gu Z, et al. 2021. Nat Genet. 53:672. PubMed
  80. Weber S, et al. 2011. J Immunol. 186:432. PubMed
Go To Top Version: 5    Revision Date: 04.21.2023

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account